Table 3.
Lipid peroxidation pattern in the studied group.
| Metabolites | SLE–Non LN | SLE–LN | Type IV Lupus Nephritis | Control | p1 | p2 |
|---|---|---|---|---|---|---|
| 4-HNE (µg/mL) | 18.17 ± 4.02 | 20.18 ± 6.08 | 19.92 ± 5.88 | 14.09 ± 1.42 | 0.04 | AB = 0.04 |
| AC = 0.04 | ||||||
| AD = 0.04 | ||||||
| BC = 0.07 | ||||||
| BD = 0.02 | ||||||
| CD = 0.02 | ||||||
| TBARs (µmol/L) | 3.04 ± 0.51 | 3.41 ± 0.66 | 3.39 ± 0.62 | 1.99 ± 0.14 | 0.03 | AB = 0.04 |
| AC = 0.03 | ||||||
| AD = 0.006 | ||||||
| BC = 0.05 | ||||||
| BD = 0.003 | ||||||
| CD = 0.004 | ||||||
| MDA (ng/mL) | 38.02 ± 5.37 | 35.11 ± 5.94 | 36.12 ± 6.01 | 20.18 ± 1.22 | 0.04 | AB = 0.08 |
| AC = 0.07 | ||||||
| AD = 0.02 | ||||||
| BC = 0.06 | ||||||
| BD = 0.04 | ||||||
| CD = 0.04 | ||||||
| 8-Isoprostan (pg/mL) | 21.80 ± 6.14 | 27.87 ± 6.15 | 28.19 ± 5.88 | 6.41 ± 0.72 | 0.007 | AB = 0.02 |
| AC = 0.03 | ||||||
| AD = 0.007 | ||||||
| BC = 0.05 | ||||||
| BD = 0.002 | ||||||
| CD = 0.003 | ||||||
| ImAnOx (μmol/L) | 259.3 ± 61.2 | 201.0 ± 77.4 | 197.12 ± 72.3 | 302.6 ± 13.1 | 0.0004 | AB = 0.03 |
| AC = 0.04 | ||||||
| AD = 0.001 | ||||||
| BC = 0.04 | ||||||
| BD = 0.0005 | ||||||
| CD = 0.0004 |
4-HNE—4-hydroxy-2-nonenal, TBARs—Thiobarbituric acid reactive substances, MDA—Malondialdehyde, ImAnOX—Total antioxidative capacity, SLE—Systemic lupus erythematosus, LN—Lupus nephritis, p—Statistical significance, p1—Triple comparison of the groups, p2—Pairwise comparison of the groups, A—SLE non-LN, B—LN, C—type IV lupus nephritis, D—Control.